Number of participants experiencing any serious adverse events · health problem or population
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Number of participants using rescue medication over 4 to 6 hours postinterventions · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Median (mean) time to use of rescue medication · health problem or population
1 finding from 1 review
Number of participants reporting an adverse event · health problem or population
Summary of Findings Table ‐ Ibuprofen showed no clear difference in number of participants reporting or experiencing any adverse event compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · health problem or population
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
At least 50% reduction in pain · health problem or population
It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants with at least 50% pain relief at 4 hours compared with active comparator (acetaminophen) (very low certainty).
2 findings from 1 review
Number of participants using rescue medication over 4 to 6 hours postinterventions · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
1 study · 5 participants
Very low
Death · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death compared with placebo (very low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes death or disability after 12 months compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether cerebrospinal fluid filtration changes improvement in disability grade Defined as achievement of a… compared with plasma exchange (very low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
Cerebrospinal fluid filtration showed no clear difference in death compared with plasma exchange (low certainty).
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes improvement in disability grade Defined as achievement of a… compared with placebo (very low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found